Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies

E. P. Alessandrino, P. Bernasconi, A. A. Colombo, D. Caldera, L. Malcovati, D. Troletti, L. Vanelli, M. Verettoni, F. Montanari, M. Lazzarino

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The aim of this study was to investigate thiotepa (TT) and fludarabine (Fluda) as a preparative regimen for allogeneic peripheral stem cell transplant in patients not eligible for a standard myeloablative regimen due to comorbidities and/or poor performance status. TT was given at a dose of 10 mg/kg over 2 days and Fluda at 125 mg/m2 over 5 days. In all, 21 patients (14 male, seven female; 10 acute leukaemia, eight myelodysplastic syndrome, two non-Hodgkin's lymphoma, one Hodgkin's disease) were treated. The median age was 51 years (range 30-55 years). All patients achieved full donor-type chimaerism. Adverse events included mild nausea and vomiting in two patients and a slight increase of serum amylase in three. A total of 13 patients received RBC transfusions (median 6U, range 1-23), and all received platelets (median 4U, range 1-27). Four patients died of nonrelapse causes and five of relapse. The 1-year probabilities of transplant-related mortality and relapse were 19 and 29%, respectively. In total, 12 patients remain in complete remission (median follow-up: 786 days). The 3-year overall survival probability was 58%. We conclude that this regimen is feasible and well tolerated.

Original languageEnglish
Pages (from-to)1039-1045
Number of pages7
JournalBone Marrow Transplantation
Volume34
Issue number12
DOIs
Publication statusPublished - Dec 2004

Fingerprint

Thiotepa
Stem Cell Transplantation
Hematologic Neoplasms
Blood Cells
Transplants
Recurrence
Myelodysplastic Syndromes
Amylases
fludarabine
Hodgkin Disease
Non-Hodgkin's Lymphoma
Nausea
Vomiting
Comorbidity
Leukemia
Blood Platelets
Tissue Donors
Survival
Mortality
Serum

Keywords

  • Allogeneic stem cell transplantation
  • Fludarabine
  • Reduced-intensity conditioning regimen
  • Thiotepa

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{f92fd57fd2154fe191609fd9ceb83ed3,
title = "Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies",
abstract = "The aim of this study was to investigate thiotepa (TT) and fludarabine (Fluda) as a preparative regimen for allogeneic peripheral stem cell transplant in patients not eligible for a standard myeloablative regimen due to comorbidities and/or poor performance status. TT was given at a dose of 10 mg/kg over 2 days and Fluda at 125 mg/m2 over 5 days. In all, 21 patients (14 male, seven female; 10 acute leukaemia, eight myelodysplastic syndrome, two non-Hodgkin's lymphoma, one Hodgkin's disease) were treated. The median age was 51 years (range 30-55 years). All patients achieved full donor-type chimaerism. Adverse events included mild nausea and vomiting in two patients and a slight increase of serum amylase in three. A total of 13 patients received RBC transfusions (median 6U, range 1-23), and all received platelets (median 4U, range 1-27). Four patients died of nonrelapse causes and five of relapse. The 1-year probabilities of transplant-related mortality and relapse were 19 and 29{\%}, respectively. In total, 12 patients remain in complete remission (median follow-up: 786 days). The 3-year overall survival probability was 58{\%}. We conclude that this regimen is feasible and well tolerated.",
keywords = "Allogeneic stem cell transplantation, Fludarabine, Reduced-intensity conditioning regimen, Thiotepa",
author = "Alessandrino, {E. P.} and P. Bernasconi and Colombo, {A. A.} and D. Caldera and L. Malcovati and D. Troletti and L. Vanelli and M. Verettoni and F. Montanari and M. Lazzarino",
year = "2004",
month = "12",
doi = "10.1038/sj.bmt.1704717",
language = "English",
volume = "34",
pages = "1039--1045",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies

AU - Alessandrino, E. P.

AU - Bernasconi, P.

AU - Colombo, A. A.

AU - Caldera, D.

AU - Malcovati, L.

AU - Troletti, D.

AU - Vanelli, L.

AU - Verettoni, M.

AU - Montanari, F.

AU - Lazzarino, M.

PY - 2004/12

Y1 - 2004/12

N2 - The aim of this study was to investigate thiotepa (TT) and fludarabine (Fluda) as a preparative regimen for allogeneic peripheral stem cell transplant in patients not eligible for a standard myeloablative regimen due to comorbidities and/or poor performance status. TT was given at a dose of 10 mg/kg over 2 days and Fluda at 125 mg/m2 over 5 days. In all, 21 patients (14 male, seven female; 10 acute leukaemia, eight myelodysplastic syndrome, two non-Hodgkin's lymphoma, one Hodgkin's disease) were treated. The median age was 51 years (range 30-55 years). All patients achieved full donor-type chimaerism. Adverse events included mild nausea and vomiting in two patients and a slight increase of serum amylase in three. A total of 13 patients received RBC transfusions (median 6U, range 1-23), and all received platelets (median 4U, range 1-27). Four patients died of nonrelapse causes and five of relapse. The 1-year probabilities of transplant-related mortality and relapse were 19 and 29%, respectively. In total, 12 patients remain in complete remission (median follow-up: 786 days). The 3-year overall survival probability was 58%. We conclude that this regimen is feasible and well tolerated.

AB - The aim of this study was to investigate thiotepa (TT) and fludarabine (Fluda) as a preparative regimen for allogeneic peripheral stem cell transplant in patients not eligible for a standard myeloablative regimen due to comorbidities and/or poor performance status. TT was given at a dose of 10 mg/kg over 2 days and Fluda at 125 mg/m2 over 5 days. In all, 21 patients (14 male, seven female; 10 acute leukaemia, eight myelodysplastic syndrome, two non-Hodgkin's lymphoma, one Hodgkin's disease) were treated. The median age was 51 years (range 30-55 years). All patients achieved full donor-type chimaerism. Adverse events included mild nausea and vomiting in two patients and a slight increase of serum amylase in three. A total of 13 patients received RBC transfusions (median 6U, range 1-23), and all received platelets (median 4U, range 1-27). Four patients died of nonrelapse causes and five of relapse. The 1-year probabilities of transplant-related mortality and relapse were 19 and 29%, respectively. In total, 12 patients remain in complete remission (median follow-up: 786 days). The 3-year overall survival probability was 58%. We conclude that this regimen is feasible and well tolerated.

KW - Allogeneic stem cell transplantation

KW - Fludarabine

KW - Reduced-intensity conditioning regimen

KW - Thiotepa

UR - http://www.scopus.com/inward/record.url?scp=19944386623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944386623&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704717

DO - 10.1038/sj.bmt.1704717

M3 - Article

C2 - 15516936

AN - SCOPUS:19944386623

VL - 34

SP - 1039

EP - 1045

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -